IDiyas

For the Inventor, By the Inventor

Millbrae, CA, United States of America

Steven H Olson

USPTO Granted Patents = 18 


 

Average Co-Inventor Count = 20.2

ph-index = 9

Forward Citations = 130(Granted Patents)


Company Filing History:

goldMedal18 out of 1,970 
 
Amgen Inc.
 patents
silverMedal1 out of 124 
 
Teijin Pharma Limited
 patents
where one patent can have more than one assignee

Years Active: 2016-2022

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):
1. 11407721 - CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer (2022-08-09),
2. 11046680 - Heteroaryl-substituted triazoles as APJ receptor agonists (2021-06-29),
3. 10736883 - Triazole furan compounds as agonists of the APJ receptor (2020-08-11),
4. 10221162 - Triazole agonists of the APJ receptor (2019-03-05),
5. 10150760 - Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor (2018-12-11),
6. 9988369 - Heterocyclic triazole compounds as agonists of the APJ receptor (2018-06-05),
7. 9868721 - Triazole agonists of the APJ receptor (2018-01-16),
8. 9845310 - Intermediates for preparing triazole agonists of the APJ receptor (2017-12-19),
9. 9758495 - Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer (2017-09-12),
10. 9751864 - Methods for preparing triazole agonists of the APJ receptor (2017-09-05),
11. 9745286 - Triazole agonists of the APJ receptor (2017-08-29),
12. 9656998 - Intermediates for preparing triazole agonists of the APJ receptor (2017-05-23),
13. 9656997 - Triazole agonists of the APJ receptor (2017-05-23),
14. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),
15. 9573936 - Triazole agonists of the APJ receptor (2017-02-21),

Title: Innovator Spotlight: Steven H Olson, Pioneering Cancer Treatment and Cardiovascular Solutions

Introduction: Steven H Olson, a distinguished inventor based in Millbrae, CA, has made groundbreaking contributions in the fields of cancer treatment and cardiovascular health. With a remarkable portfolio of 18 patents, Olson has significantly impacted the medical industry through his innovative research and developments.

Latest Patents: Olson's recent patents showcase his expertise in developing novel compounds for cancer therapy and cardiovascular conditions. His inventions include CIS-morpholinone and other compounds as MDM2 inhibitors for cancer treatment, as well as heteroaryl-substituted triazoles as APJ receptor agonists for addressing cardiovascular ailments. These inventions reflect his commitment to advancing medical science and improving patient outcomes.

Career Highlights: Notably, Steven H Olson is affiliated with Teijin Pharma Limited, a prominent pharmaceutical company known for its cutting-edge research and development efforts. Within the company, Olson has played a pivotal role in spearheading innovative projects and driving technological advancements in the healthcare sector. His strategic vision and scientific acumen have positioned him as a key figure in the realm of medical innovations.

Collaborations: Throughout his career, Olson has collaborated with esteemed professionals in the field, including Xiaoqi Chen and Richard V Connors. These synergistic partnerships have fueled collaborative research initiatives and fostered a dynamic exchange of ideas, resulting in the creation of impactful solutions for complex medical challenges.

Conclusion: In conclusion, Steven H Olson's inventive spirit, coupled with his dedication to advancing healthcare technologies, has established him as a trailblazing figure in the realms of cancer research and cardiovascular medicine. His patents stand as testament to his ingenuity and unwavering commitment to making a difference in the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…